Recece Pharmaceuticals Bolsters R&D with A$973,144 Advance!

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is thrilled to announce the receipt of additional non-dilutive funds from Radium Capital (Radium) in the amount of A$973,144 to support Recce’s new class of synthetic anti-infectives research and development. This tax incentive will play an invaluable role in the future success of Recce’s innovative R&D.

Recce Pharmaceuticals is delighted to receive an A$973,144 advance that will provide essential assistance in reaching the imminent clinical goals. “This is a fantastic boost that will take us a step closer to our objectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

The Company has recently received a tremendous boost to its Research and Development budget, with an accountant-verified portion of its December 2022 – February 2023 R&D expenditure already paid in advance! This non-dilutive contribution adds to the A$1,908,039 already reported, totalling an impressive A$2,881,183 of R&D credits for the current financial year.

The Australian Government’s generous 43.5% R&D Tax Incentive rebate can be applied to R&D activities conducted overseas, with strong ties to the country and meeting specific criteria. This generous incentive provides a great opportunity for businesses to access significant savings on their research and development investments, both at home and abroad.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is on the cutting edge of medical science, developing a revolutionary new class of Synthetic Anti-Infectives to tackle some of the world’s most pressing health issues: antibiotic-resistant superbugs and emerging viral pathogens. With their innovative approach, Recce is at the forefront of the fight against these dangerous illnesses.

Recce has developed an impressive anti-infective pipeline that utilizes three patented, broad-spectrum, synthetic polymer anti-infectives. RECCE® 327 is a powerful intravenous and topical therapy created to treat serious and potentially life-threatening infections caused by Gram-positive and Gram-negative bacteria, including their superbug forms. RECCE® 435 is an orally administered therapy that targets bacterial infections.

Meanwhile, RECCE® 529 is designed to fight viral infections. These anti-infectives are set to revolutionize the field of medicine, as their multi-layered mechanisms of action have the potential to overcome the hypercellular mutation of bacteria and viruses – a challenge that no existing antibiotic has been able to tackle.

The FDA has awarded RECCE® 327 unparalleled recognition as the first and only synthetic polymer and sepsis drug candidate in the world. Qualified as a Qualified Infectious Disease Product under the Generating Antibiotic Initiatives Now (GAIN) Act, it has been granted Fast Track Designation and a 10-year market exclusivity post approval.

This milestone has earned RECCE® 327 a place on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline. Despite the exciting progress, RECCE® 327 is still in the early stages of development and requires further clinical testing to assess its safety and efficacy.

Recce is revolutionizing the medical industry with its automated manufacturing capabilities, which are currently supporting clinical trials. Its anti-infective pipeline is designed to meet unmet medical needs through the utilization of its unique technologies, driving forward a new era of healthcare.

Leave a Comment